Intract Pharma

Intract Pharma is a private, preclinical-stage biotech specializing in oral drug delivery platforms for biologics. Founded in 2006 as a spin-out from University College London (UCL), the company leverages over two decades of research to develop technologies that target drug release to specific regions of the GI tract, aiming to replace injectable therapies with oral tablets or capsules. Its lead program is an oral anti-TNFα antibody, and the company is pursuing strategic moves, including a planned merger with Tharimmune, to advance its pipeline. Intract operates as a platform company, likely seeking licensing deals and partnerships to develop oral formulations of biologic drugs.

Soteria® for oral delivery of biologics (e.g., monoclonal antibodies) and Phloral® for precise colon-targeted delivery. Both use pH and enzymatic triggers for site-specific release in the GI tract.

Intract competes in the crowded and high-stakes field of oral biologic delivery. Competitors include platform companies like Rani Therapeutics (mechanical pill), Entera Bio (peptides), and large pharma divisions. Differentiation relies on the specific mechanistic approach and preclinical/clinical validation.